home All News open_in_new Full Article

Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars

AMSTERDAM & ZUG, Switzerland & GDAŃSK, Poland — Polpharma Biologics S.A. (“Polpharma Biologics”), specialized in the development and manufacturing of biosimilars, today announced that it has signed licensing agreements with MS Pharma, a leading biosimilar production and distribution company in the Middle East and North Africa (MENA) region, for the commercialization of its biosimilar candidates […]


today 1 week ago attach_file Other

attach_file Politics
attach_file Other
attach_file Politics
attach_file Other
attach_file Other
attach_file Economics
attach_file Society
attach_file Economics
attach_file Economics
attach_file Other
attach_file Society
attach_file Economics
attach_file Events
attach_file Economics
attach_file Other
attach_file Economics
attach_file Sport
attach_file Other
attach_file Technology
attach_file Other


ID: 3977811553
Add Watch Country

arrow_drop_down